The effects of calcipotriol and methylprednisolone aseponate on bcl-2, p53 and ki-67 expression in psoriasis

Journal of the European Academy of Dermatology and Venereology

Volumn 20, Issue 5, 2006, Pages 527-533

  Adisen, E ^a   Gulekon A ^a   Erdem, O ^a   Dursun, A ^a   Gurer M A ^a  

^a GAZI UNIVERSITY   (Turkey)

Author keywords

bcl 2; ki 67; p53; Psoriasis

Indexed keywords

CALCIPOTRIOL; KI 67 ANTIGEN; METHYLPREDNISOLONE ACEPONATE; PROTEIN BCL 2; PROTEIN P53;

ADULT; ARTICLE; CHRONIC DISEASE; CLINICAL ARTICLE; CLINICAL PROTOCOL; CONTROLLED STUDY; DISEASE SEVERITY; DRUG EFFECT; DRUG MECHANISM; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; KERATINOCYTE; MALE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PSORIASIS; SCORING SYSTEM; SKIN BIOPSY; STATISTICAL ANALYSIS; TREATMENT OUTCOME;

ADMINISTRATION, TOPICAL; ADULT; APOPTOSIS; BCL-2-ASSOCIATED X PROTEIN; CALCITRIOL; DERMATOLOGIC AGENTS; FEMALE; HUMANS; KI-67 ANTIGEN; MALE; METHYLPREDNISOLONE; MIDDLE AGED; PSORIASIS; STATISTICS, NONPARAMETRIC; TREATMENT OUTCOME; TUMOR SUPPRESSOR PROTEIN P53;

EID: 33646075434     PISSN: 09269959     EISSN: 14683083     Source Type: Journal    
DOI: 10.1111/j.1468-3083.2006.01508.x     Document Type: Article

References (37)

1. Christophers E, Mrowietz U. Psoriasis. In: Freedberg IM, Eisen AZ, Wolf K et al., eds. Dermatology in General Medicine, 5th edn. McGraw-Hill, New York, 1999: 495-521.
2. Braun-Falco O, Plewig G, Wolff HH, Burgdorf WHC. Dermatology, 2nd edn. Springer-Verlag, Berlin, 2000: 585-610.
3. Van Steensel MAM, Steijlen PM. Genetics of psoriasis. Clin Dermatol 1997; 15: 669-675.
4. Baskan EB, Tunali Ş, Filiz G, Aydoǧan K, Sarýcaoǧlu H. Psoriasis lezyonlarýnda ki-67, PCNA, bcl-2 ve p53 protein ekspresyonlarýnýn immunohistokimyasal yöntemle dederlendirilmesi. T Klin Dermatoloji 2001; 11: 68-72.
5. Cohen JJ. Apoptosis. Immunol Today 1993; 114: 126-130.
6. Raskin CA. Apoptosis and cutaneous biology. J Am Acad Dermatol 1997; 36: 885-896.
7. Haake AR, Polakowska RR. Cell death by apoptosis in epidermal biology. J Invest Dermatol 1993; 101: 107-112.
8. Wrone-Smith T, Mitra RS, Thompson CB, Jasty R, Castle VP, Nickloff BJ. Keratinocytes derived from psoriatic plaques are resistant to apoptosis compared with normal skin. Am J Pathol 1997; 151: 1321-1329.
9. Bianchi L, Farrace MG, Nini G, Piacentini M. Abnormal bcl-2 and tissue transglutaminase expression in psoriatic skin. J Invest Dermatol 1994; 103: 829-883.
10. Hannuksela-Svahn A, Paakko P, Autio P, Reunala T, Karvonen J, Vahakangas K. Expression of p53 protein before and after PUVA treatment in psoriasis. Acta Derm Venereol 1999; 79: 195-199.
11. Distelhorst CW. Recent insights into the mechanism of glucocorticosteroid-induced apoptosis. Cell Death Differ 2002; 1: 6-19.
12. Lee E, Jeon SH, Younyi J, Jin YJ, Son YS. Calcipotriol inhibits autocrine phosphorylation of EGF receptor in a calcium dependent manner, a possible mechanism for its inhibition of cell proliferation and stimulation of cell differentiation. Biochem Biophys Res Commun 2001; 284: 419-425.
13. Reichrath J, Müller SM, Kerber A, Baum HP, Bahmer FA. Biologic effects of topical calcipotriol (MC 903) treatment in psoriatic skin. J Am Acad Dermatol 1997; 36: 19-28.
14. Wang X, Studzinski GP. Antiapoptotic action of 1,25-Dihydroxyvitamin D3 is associated with increased mitocondrial MCL-1 and RAF-1 proteins and reduced release of cytocrome C. Exp Cell Res 1997; 235: 210-217.
15. Van de Kerkhof PCM, Green C, Hamberg KJ et al. Safety and efficacy of combined high-dose treatment with calcipotriol ointment and solution in patients with psoriasis. Dermatology 2002; 204: 214-221.
16. Marks R, Barton SP. Assessment of disease progress in psoriasis. Arch Dermatol 1989; 125: 235-240.
17. Wrone-Smith T, Johnson T, Nelson B et al. Discordant expression of bcl-x and bcl-2 by keratinocytes in vitro and psoriatic keratinocytes invivo. Am J Pathol 1995; 146: 1079-1088.
18. Tamada Y, Tamada H, Kitamura T et al. Identification of programmed cell death in normal skin tissues by using specific labelling of fragmanted DNA. Br J Dermatol 1994; 131: 521-524.
19. McCall CA, Cohen JJ. Programmed cell death in terminally differentiating keratinocytes: Role of endogenous endonuclease. J Invest Dermatol 1991; 97: 111-114.
20. Laporte M, Galand P, Fokan D, Graef C, Heenen MA. Apoptosis in established and healing psoriasis. Dermatology 2000; 200: 314-316.
21. Sepp N, Linser I, Hinter H, Fritsch P. Disturbed epidermal homeostasis in psoriasis. J Invest Dermatol 1990; 95: 488.
22. Toussaint S, Kamino H. Noninfectious erythematous papular and squamous diseases. In: Elder D, Elenitas R, Jaworsky C, Johnson B, eds. Lever's Histopathology of the Skin, 8th edn. Lipincott Raven Publications, New York, 1997: 156-163.
23. Ozawa M, Ferenczi K, Kikuchi T et al. 312-nanometer Ultraviolet B light (narrow-band UVB) induces apoptosis of T cells within psoriatic lesions. J Exp Med 1999; 189: 711-718.
24. Gasparro FP. p53 in dermatology. Arch Dermatol 1998; 134: 1029-1030.
25. Soini Y, Kamel D, Paakko P, Lehto PV, Quikarinen A, Vahakangas K. Aberrant accumulation of p53 associates with ki-67 and mitotic count in benign skin lesions. Br J Dermatol 1994; 131: 514-520.
26. Tadini G, Cerri A, Crosti L, Cattoretti G, Berti E. p53 and oncogenes expression in psoriasis. Acta Derm Venereol Suppl (Stockh) 1989; 146: 33-35.
27. Solary E, Dubrez L, Eymin B. The role of apoptosis in the pathogenesis and treatment of diseases. Eur Respir J 1996; 9: 1293-1305.
28. Helander SD, Peters MS, Pittelkow MR. Expression of p53 protein in benign and malignant epidermal pathologic conditions. J Am Acad Dermatol 1993; 29: 1993.
29. Mathlashewski G, Banks L, Pim D. Analysis of human p53 proteins and mRNA levels in normal and transformed cells. Eur J Biochem 1986; 54: 665-672.
30. Kastan MB, Radin AI, Kuerbitz SJ. Levels of p53 protein increase with maturation in human hematopoetic cells. Cancer Res 1991; 51: 4279-4286.
31. Healy E, Reynolds NJ, Smith MD. Up-regulation of p21 WAF1/CIP1 in psoriasis and after the application of irritants and tape stripping. J Invest Dermatol 1993; 105: 274-279.
32. Van Ruissen F, Van de Kerkhof PCM, Schalkwijk J. Signal transduction pathways in epidermal proliferation and cutaneous inflamation. Clin Dermatol 1995; 13: 161-190.
33. Sawhney N, Hall PA. Ki-67-structure, function and new antibodies. J Pathol 1992; 168: 161-162.
34. Ando M, Kawashima T, Kobayashi H, Ohkawara A. Immunohistological detection of proliferating cells in normal and psoriatic epidermis using ki-67 monoclonal antibody. J Dermatol Sci 1990; 1: 441-446.
35. Caldwell CJ, Hobbs C, Mckee PH. The relationship of ki-67 and involucrin expression in proliferative, preneoplastic and neoplastic skin. Clin Exp Dermatol 1997; 22: 11-16.
36. Sellheyer K, Krahl D, Ratech H. Distribution of bcl-2 and bax in embryonic and fetal human skin. Am J Dermatopathol 2001; 23: 1-7.
37. Koçak M, Bozdoǧan Ö, Erkek E, Atasoy P, Birol A. Examination of bcl-2, bcl-x and bax protein in psoriasis. Int J Dermatol 2003; 42: 789.